

**FORM 51-102F3**  
**MATERIAL CHANGE REPORT**

**Item 1 Name and Address of Company**

MyndTec Inc. (the “**Company**” or “**MyndTec**”)  
1900 Minnesota Court, Suite 122  
Mississauga, Ontario  
L5N 3C9

**Item 2 Date of Material Change**

July 13, 2023.

**Item 3 News Release**

Attached as Schedule “A” hereto is a copy of a news release relating to the material change, which was disseminated on July 13, 2023, through Newsfile Corp. The news release was subsequently filed on the System for Electronic Document Analysis and Retrieval at [www.sedar.com](http://www.sedar.com).

**Item 4 Summary of Material Change**

On July 13, 2023, the Company closed its previously announced non-brokered private placement of 540,088 units of the Company (the “**Units**”) at a price of \$0.70 per Unit (the “**Issue Price**”) for aggregate gross proceeds to the Company of \$378,061.60 (the “**Offering**”).

**Item 5 Full Description of Material Change**

*(a) a description of the transaction and its material terms*

On July 13, 2023, the Company closed its previously announced non-brokered private placement of 540,088 common shares, with a single subscriber, at the Issue Price for aggregate gross proceeds to the Company of \$378,061.60.

The Offering did not constitute a “related party transaction” within the meaning of Multilateral Instrument 61-101 – *Protection of Minority Security Holders in Special Transactions* (“**MI61- 101**”) as no insiders of the Company participated in the Offering.

*(b) the purpose and business reasons for the transaction*

The Company intends to use the net proceeds of the Offering to settle a legacy debt owed to the subscriber.

*(c) the anticipated effect of the transaction on the issuer's business and affairs*

The Offering will provide the Company with funds to be used in accordance with Item 5(b) above.

- (d) *a description of (i) the interest in the transaction of every interested party and of the related parties and associated entities of the interested parties, and (ii) the anticipated effect of the transaction on the percentage of securities of the issuer, or of an affiliated entity of the issuer, beneficially owned or controlled by each person referred to in subparagraph (i) for which there would be a material change in that percentage.*

Pursuant to the Offering, the Company issued:

- (i) None  
(collectively, the “**Insiders**”).

The effect of the Offering did not have a material change on the percentage of securities of the Company beneficially owned or controlled by any Insider referred to above.

- (e) *unless this information will be included in another disclosure document for the transaction, a discussion of the review and approval process adopted by the board of directors and the special committee, if any, of the issuer for the transaction, including a discussion of any materially contrary view or abstention by a director and any material disagreement between the board and the special committee.*

A resolution of the board of directors of the Company was passed in accordance with the *Business Corporations Act* (Ontario) approving the Offering. No special committee was established in connection with the Offering, and no materially contrary view or abstention was expressed or made by any director.

- (f) *a summary of the formal valuation, if any, obtained for the transaction*

Not applicable.

- (g) *disclosure of every prior valuation in respect of the issuer that relates to the subject matter of is otherwise relevant to the transaction (i) that has been made in the 24 months before the date of the material change report, and (ii) the existence of which is known, after reasonable enquiry, to the issuer or to any director or senior officer of the issuer*

Not applicable.

- (h) *the general nature and material terms of any agreement entered into by the issuer, or a related party of the issuer, with an interested party or a joint actor with an interested party, in connection with the transaction*

No Insiders participated in the Offering.

*(i) disclosure of the formal valuation and minority approval exemptions, if any, on which the issuer is relying on, and the facts supporting reliance on the exemptions.*

Not Applicable.

For additional details of the material change, please see the news release attached as Schedule "A" hereto.

**Item 6 Reliance on subsection 7.1(2) of National Instrument 51-102**

Not applicable.

**Item 7 Omitted Information**

Not applicable.

**Item 8 Executive Officer**

The following executive officer is knowledgeable about the material change and may be contacted about this report:

Craig Leon  
Chief Executive Officer  
(416) 569-0430

**Item 9 Date of Report**

July 13, 2023

**SCHEDULE "A"**

*[See Attached]*

# MyndTec Inc. Closes Previously Announced Shares for Debt Transaction

**NOT FOR DISTRIBUTION TO U.S. NEWS WIRE SERVICES OR DISSEMINATION IN THE UNITED STATES.**

**Mississauga, Ontario, July 13, 2023** – MyndTec Inc. ("MyndTec" or the "Company") (CSE: MYTC), an emerging force in neurological treatment and rehabilitation, is pleased to announce that further to its news release dated July 6, 2023, it has issued 540,088 common shares in the capital of the Company (the "Common Shares") at a price of \$0.70 per share to an arm's length creditor (the "Creditor") in settlement of \$378,061.60 worth of debt owed by the Company to the Creditor pursuant to a debt settlement agreement dated May 29, 2023 (the "Debt Settlement Agreement"). The Common Shares were issued to the Creditor pursuant to a prospectus exemption and will be subject to resale restrictions during a period of four months and a day from the date of issuance in accordance with applicable securities laws.

For more details on the Debt Settlement Agreement, the agreements pursuant to the Debt Settlement Agreement, and the transaction, please refer to the news release dated July 6, 2023, a copy of which has been made available under the Company's SEDAR profile.

## About MyndTec

MyndTec is a Canadian medical technology company dedicated to the development and commercialization of innovative products that improve function, maximize independence and enhance the quality of life for individuals who have suffered injury to the central nervous system as a result of stroke, spinal cord injury and certain traumatic brain injuries. The Company develops non-invasive neurological and nervous system electrical stimulation therapeutics for the treatment of neurological diseases and injury specifically targeted to markets with large, growing and global patient populations.

The Company's flagship product MyndMove™ is a non-invasive functional electrical stimulation-based intervention. MyndMove™ uses neuroplasticity mechanisms to stimulate development of new neural efferent and afferent pathways allowing patients to re-establish voluntary movement and improve independence in their activities of daily living. The MyndMove™ system offers trained therapists the ability to assist individuals affected with paralysis to improve voluntary control of their limbs. The MyndMove™ therapy system offers a broad spectrum of sophisticated functional electrical stimulation software protocols which therapists customize to patient needs to enable meaningful controlled movements via proprietary stimulation technology.

For more information visit <https://www.myndtec.com>

## Contact Information

Craig Leon  
MyndTec Inc. | Chief Executive Officer  
investor.relations@myndtec.com  
Tel: (416) 569-0430

Bill Mitoulas  
Venture North Capital Inc. | Principal

billm@venturenorthcapital.com  
Tel: (416) 479-9547

### **Cautionary Note Regarding Forward-Looking Statements**

This news release contains forward-looking statements that constitute “forward-looking information” within the meaning of applicable Canadian securities laws (collectively “**forward-looking statements**”). All statements in this news release that are not historical facts are forward-looking statements, including, but not limited to, all statements regarding: events, performance or results of operations that the Company believes, expects or anticipates will or may occur in the future. Forward-looking statements are typically, but not always, identified by words such as: “believes”, “expects”, “aim”, “anticipates”, “intends”, “estimates”, “plans”, “may”, “should”, “could”, “continue”, “would”, “will”, “potential”, “scheduled”, “goal”, “target”, or variations of such words and phrases and similar expressions, which, by their nature, refer to future events or results that may, could, would, might or will occur or be taken or achieved. Forward-looking statements are necessarily based on a number of estimates and assumptions that include, but are not limited to: expected future development; general economic conditions; the ability of the Company to execute on its business objectives; and other estimates and assumptions described in the Company’s Listing Statement dated February 18, 2022 (the “**Listing Statement**”), a copy of which is available under the Company’s profile on SEDAR at [www.sedar.com](http://www.sedar.com). Forward-looking statements are inherently subject to a number of significant risks and uncertainties that could cause the actual results or events to differ materially from those described in the forward-looking statements. Important risks and uncertainties that could cause actual results or events to differ materially from expectations include, but are not limited to: the Company’s ability to continue as a going concern, the Company’s research, development and commercialization of its products could be stopped or delayed if any third party fails to provide sufficient quantities of products or components, or fails to do so at acceptable quality levels or prices, or fails to maintain or achieve satisfactory regulatory compliance; the Company expects to incur significant ongoing costs and obligations relating to its investment in infrastructure, growth, research and development, regulatory compliance and operations; and other risks and uncertainties described in the Listing Statement. The Company has attempted to identify important factors that could cause actual results, performance or achievements to vary from those expectations expressed or implied by the forward-looking statements, however, there may be other factors that cause results, performance or achievements not to be as expected and that could cause actual results, performance or achievements to differ materially from current expectations. These forward-looking statements are only current as of the date of this news release. Although the Company believes that the expectations reflected in such forward-looking statements are reasonable, such statements involve risks and uncertainties and the Company provides no assurance that they will prove to be correct. Readers should not place undue reliance on such forward-looking statements. The Company does not undertake any obligation to update forward-looking statements contained herein, other than as required by applicable law. All forward-looking statements are qualified in their entirety by this cautionary statement.

**The CSE has in no way passed upon the merits of the business of the Company and has neither approved nor disapproved the contents of this news release and accepts no responsibility for the adequacy or accuracy hereof.**